ABBV-383 (Etentamig)
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immunoglobulin Light Chain (AL) Amyloidosis
Conditions
Immunoglobulin Light Chain (AL) Amyloidosis
Trial Timeline
Apr 1, 2024 → Sep 1, 2031
NCT ID
NCT06158854About ABBV-383 (Etentamig)
ABBV-383 (Etentamig) is a phase 1/2 stage product being developed by AbbVie for Immunoglobulin Light Chain (AL) Amyloidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06158854. Target conditions include Immunoglobulin Light Chain (AL) Amyloidosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06158854 | Phase 1/2 | Recruiting |
Competing Products
11 competing products in Immunoglobulin Light Chain (AL) Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| zigakibart | Novartis | Phase 2 | 52 |
| iptacopan | Novartis | Phase 3 | 77 |
| CCX168 | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Rilzabrutinib + Placebo + Glucocorticoid | Sanofi | Phase 3 | 76 |
| rilzabrutinib + Glucocorticoids | Sanofi | Phase 2 | 51 |
| Felzartamab | Biogen | Phase 2 | 49 |
| Felzartamab + Placebo | Biogen | Phase 3 | 74 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| sparsentan + irbesartan + Dapagliflozin | Travere Therapeutics | Phase 3 | 72 |